Quick Facts: Monteluk

• Asthma: Helps manage and prevent the symptoms of chronic asthma.
• Exercise-Induced: Assists in the prevention of breathing difficulties brought on by exercise.
• Allergic Rhinitis: Aids in controlling the symptoms associated with seasonal and perennial allergies.

---

Monteluk is a prescription medication utilized to support the management of several respiratory and allergy-related conditions. It is indicated for the chronic treatment and prevention of asthma symptoms in adults and pediatric patients aged 12 months and older. Regular use helps reduce the incidence of wheezing, chest tightness, and coughing associated with asthma.

Monteluk also contributes to the acute prevention of exercise-induced bronchoconstriction (EIB), which involves breathing difficulties triggered by physical activity. For this indication, it is intended for use in patients aged 6 years and older.

Additionally, this compound is approved to provide relief from the symptoms of allergic rhinitis, commonly known as hay fever. This applies to both seasonal and perennial (year-round) allergic symptoms. The use of this drug for allergic rhinitis is typically reserved for patients who have an inadequate response or intolerance to other alternative therapies.

Regulatory References

1. NIH MedlinePlus guidance

Montelukast (Monteluk) is primarily indicated for the chronic treatment and prevention of asthma and the relief of symptoms of allergic rhinitis.

Most adults and children aged 6 months and older can use this medication, with specific age requirements depending on the condition being treated:

• Asthma: Approved for use in patients 12 months of age and older.
• Exercise-Induced Bronchoconstriction (EIB): Approved for prevention in patients 6 years of age and older.
• Seasonal Allergic Rhinitis (SAR): Approved for patients 2 years of age and older.
• Perennial Allergic Rhinitis (PAR): Approved for patients 6 months of age and older.

---

Contraindications and Precautions

Montelukast is contraindicated in patients with a known hypersensitivity or allergy to the drug or any of its components. Additionally, Montelukast must not be used to treat an acute asthma attack; patients should have appropriate rescue medication available.

Caution is advised, and your healthcare provider must be informed, if the patient has:

• A history of mental health problems (e.g., depression, anxiety, suicidal thoughts) due to reports of neuropsychiatric side effects.
• Phenylketonuria (PKU), as the chewable tablet formulations contain aspartame (a source of phenylalanine).
• Liver disease (hepatic insufficiency).

Patients with aspirin sensitivity should continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while taking Montelukast.

Interactions with other medicines and products

The interaction profile of Monteluk (Montelukast) is primarily defined by its metabolism via specific cytochrome P450 (CYP) enzymes and through formulation-related constraints documented in official prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

Category	Statement	Constraint
Exposure Increase	Co-administration with Gemfibrozil (an inhibitor of CYP 2C8 and 2C9) results in an approximately 4.4-fold increase in the systemic exposure (AUC) of Montelukast.	Use with caution.
Exposure Decrease	Phenobarbital (a CYP inducer) results in an approximate 40% decrease in Montelukast systemic exposure (AUC).	Caution required, especially in children.
Lack of Effect	Montelukast did not have clinically important effects on the pharmacokinetics of co-administered Theophylline, Warfarin, Digoxin, or oral contraceptives.	No dosage modification required for these drugs.
Aspirin/NSAIDs	Patients with known aspirin sensitivity must continue to avoid Aspirin and Non-Steroidal Anti-Inflammatory Agents (NSAIDs).	Mandatory avoidance for sensitive individuals.

Formulation and Timing Constraints

Montelukast is a substrate for CYP 2C8, 2C9, and 3A4 enzymes, which explains the documented metabolic interactions. Caution is specifically noted for pediatric patients when co-administering Monteluk with potent CYP inducers like Rifampicin. Furthermore, the oral granule formulation, when mixed with food or liquid, must be administered within 15 minutes of preparation. The 4-mg and 5-mg chewable tablets contain phenylalanine and should be noted for patients with Phenylketonuria (PKU).

Mechanism of Action: How Monteluk Works

Molecular Targeting of the Leukotriene Receptor

This molecule initiates its action by highly selective and competitive antagonism of the Cysteinyl Leukotriene Receptor Type 1 ( CysLT1 R), primarily expressed on cells within the respiratory system. By binding to this receptor, the molecule prevents the attachment of potent inflammatory mediators (Cysteinyl Leukotrienes), thereby suppressing the activation of a key G-protein-coupled signaling cascade.

Modulation of Airway Muscle Tone and Fluid Dynamics

The blockade of the CysLT1 R results in decreased intracellular signaling responsible for the contraction of airway smooth muscle. This mechanism also reduces the CysLT-mediated increase in vascular permeability, leading to decreased fluid extravasation (edema) in the airway walls.

Modification of Inflammatory Cell Activity

The molecule influences inflammatory regulation by interrupting the chemical signals responsible for the movement and activation of specific white blood cells, particularly eosinophils. This action restricts the chemotaxis and activation of these cells, altering the inflammatory response in the tissue by limiting the chronic presence of CysLT-sensitive cells.

Montelukast is administered via the oral route for systemic use as a chronic maintenance treatment. The standard regimen requires taking the medicine once daily, and for chronic asthma management, this dose is preferably taken in the evening. The official dosing is strictly dependent on age. Adults and adolescents aged 15 years and older take a 10 mg film-coated tablet daily. Pediatric patients aged 6 to 14 years are prescribed a 5 mg chewable tablet, while children 6 months to 5 years old are prescribed 4 mg, available as a chewable tablet or oral granules.

The medicine should be taken daily for sustained effect, even during periods when symptoms are controlled. If a dose is missed, it should be skipped, and the patient should resume the next scheduled dose at the usual time; doubling the dose is not permitted. The chewable and film-coated tablets can be consumed with or without food. For the oral granules, strict administration rules apply: they must be administered within 15 minutes of mixing with a spoonful of cold or room temperature soft food, breast milk, or formula, and the mixture must not be stored for later use. When Montelukast is used specifically for the prevention of exercise-induced bronchoconstriction (EIB), a separate 10 mg dose may be taken at least two hours before exercise, but only if the patient is not already taking a daily dose for other reasons. No dose adjustment is required for geriatric patients or those with mild-to-moderate renal or hepatic impairment.

Research Evidence / Overview of Studies for Monteluk

---

Evidence for Use in Chronic Asthma Maintenance

Research has been placed on the evaluation for chronic asthma management. Studies utilize sophisticated Randomized Controlled Trials (RCTs) and meta-analyses to examine changes in objective functional lung measures (e.g., FEV1) and patient-reported outcomes like symptom scores. Comparisons against Inhaled Corticosteroids (ICS) show that measurements for certain endpoints, such as night-time symptoms, differed from those reported for ICS. Data also indicates interindividual variability in patient response.

---

Evidence for Use in Preventing Exercise-Induced Bronchoconstriction (EIB)

Montelukast was evaluated in highly controlled trials involving a standardized exercise challenge. The primary outcome examined was the maximum percent fall in FEV1 following the test. Single-dose use was observed in relation to this fall for up to 24 hours. The evidence is derived from settings with controlled conditions, and Longer-term data on repeated, daily use purely for EIB prevention is not extensively documented.

---

Evidence for Use in Allergic Rhinitis Symptoms

For symptoms related to allergic rhinitis, short-term RCTs explored outcomes related to physical discomfort, primarily measuring changes in the Total Nasal Symptom Score (TNSS). Comparative studies described changes in nasal symptoms as distinct from what was observed with topical nasal steroid therapies. Systematic reviews suggest the compound was associated with measured changes similar to existing first-line therapies. Limited information for long-term outcomes exists for AR symptoms alone.

---

Consistency of Findings and Research Uncertainty

Research includes specific studies in pediatric patients across various age strata and those with comorbid conditions (asthma and rhinitis). While research contributes to the evidence landscape, certainty remains low in certain areas. Post-market observations related to neuropsychiatric events have contributed to regulatory review, and further research is ongoing to clarify the full context of these observed effects.

Common questions about Monteluk (FAQ)

---

Q: Can I use Monteluk to treat a sudden asthma attack?

No. Official product information states that Monteluk (Montelukast) is not intended to treat an acute or sudden asthma attack. It is designed only as a daily, chronic maintenance treatment to help manage asthma symptoms over time. For acute attacks, it is important that patients have an appropriate rescue inhaler or medication available, as this product is not for acute use.

---

Q: What is the maximum daily dose for an adult?

According to regulatory guidelines, the maximum recommended daily dose for adults is one 10 mg tablet. This single dose is used for chronic asthma, allergic rhinitis, and for the prevention of exercise-induced bronchoconstriction (EIB). Official prescribing information indicates that a patient already taking a daily dose is typically not advised to take an additional dose for EIB prevention within the same 24-hour period.

---

Q: Are there special instructions for giving the oral granules to a child?

Yes, there are specific administration rules for the oral granule formulation. Regulatory documents state the granules can be swallowed whole or mixed with a spoonful of cold or room temperature soft food, such as applesauce, or a teaspoon of breast milk or baby formula. Official instructions specify that the mixed dose should be administered within 15 minutes of preparation and should not be stored for later use.

---

Q: What is the specific risk of taking Montelukast if I have a history of depression or anxiety?

Official product information, including the Boxed Warning in some regions, warns about potential serious neuropsychiatric events. These events can include changes in behavior and mood, such as agitation, depression, and suicidal thoughts, and have been reported in patients both with and without a prior mental health history. The product labeling advises that patients and caregivers should be observant for any new or worsening mood or behavioral changes while taking this medication.

---

Q: How long does it take for Montelukast to start working after the first dose?

For the chronic management of asthma, improvements in symptoms and lung function are generally observed within 24 hours of starting daily therapy. However, the full benefit for chronic conditions may take several weeks to be achieved. For preventing exercise-induced bronchoconstriction (EIB), the single dose is intended to be taken at least two hours before exercise.

---

Q: How long can I take Montelukast safely? Is it for short-term or long-term use?

Official information defines Montelukast as a chronic treatment indicated for the long-term maintenance of asthma and the relief of allergic rhinitis symptoms. It is not typically considered a short-term drug. It is taken for sustained periods as part of chronic treatment, the duration of which is determined by a healthcare professional.

Storage and Disposal Requirements for Montelukast

Montelukast products must be stored strictly according to the conditions documented in regulatory labeling to maintain stability.

Storage Classification	Official Requirement
Temperature	Store at controlled room temperature (20 C to 25 C), permitting excursions up to 30 C.
Protection	Keep in the original container and protect from light and moisture.
Stability	Multi-dose bottle packs have an in-use shelf life of 30 days after opening.
Child Safety	Must be stored out of the sight and reach of children.

Disposal instructions require that any unused or expired Montelukast product be discarded in accordance with local requirements. The medicine must not be disposed of via wastewater or routine household trash.